Biogen Inc. (BIIB) was upgraded to a "buy" by TheStreet's Quant Ratings service on Wednesday. This biotech name has made a chart that could be challenging to many traders and investors. Let's drill down and see if an easier approach to the long side can be found.
More from Stocks
TG Therapeutics and Exelixis could find themselves on the shopping lists of other companies.
The Fed is on pause as far as targeting short term rates goes, and that is how it should be at this time.
Whether or not tariff increases are delayed or not is the only short-term catalyst that really matters.
The Cheesecake Factory posted reasonably good growth since 2010, but recent price action has been poor, taking the shares down from a 52-week high -- and making the name bargain.
Let's look at some strange moves in the Volatility Index that left the S&P 500 behind, the McClellan Summation Index's failure to turn up, and trade news and see if the Market even knows what it's looking for.